{"id":1319,"date":"2020-04-24T07:18:00","date_gmt":"2020-04-24T07:18:00","guid":{"rendered":"https:\/\/aceoncology.org\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations"},"modified":"2021-03-05T05:18:27","modified_gmt":"2021-03-05T05:18:27","slug":"japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/","title":{"rendered":"Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations"},"content":{"rendered":"\n<p>A subset of lung adenocarcinomas (3-4%) harbor oncogenic alterations in the&nbsp;<em>MET<\/em>&nbsp;exon 14 (<em>MET<\/em>ex14) splice sites that cause exon 14 skipping. These alterations are associated with increased tumor aggressiveness and poor prognosis. However, <a href=\"https:\/\/www.lungcancerjournal.info\/article\/S0169-5002(16)30527-X\/fulltext#sec0045\" target=\"_blank\" rel=\"noreferrer noopener\">emerging data<\/a> suggest that lung adenocarcinomas harboring <em>MET<\/em>ex14-skipping alterations are sensitive to c-Met kinase inhibitors. On 25 March 2020, the Japanese Ministry of Health, Labour and Welfare (MHLW) granted <a href=\"https:\/\/www.prnewswire.com\/news-releases\/tepmetko-tepotinib-approved-in-japan-for-advanced-nsclc-with-metex14-skipping-alterations-301029496.html\" target=\"_blank\" rel=\"noreferrer noopener\">regulatory approval<\/a> for the highly selective, oral MET inhibitor, tepotinib (Tepmetko\u00ae, Merck KGaA), for the treatment of patients with advanced NSCLC harboring <em>MET<\/em>ex14<em>&#8211;<\/em>skipping alterations.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>This approval is based on results from the ongoing, single-arm <a href=\"https:\/\/meetinglibrary.asco.org\/record\/174241\/abstract\" target=\"_blank\" rel=\"noreferrer noopener\">phase II VISION trial<\/a> that includes treatment naive and previously treated patients with advanced <em>MET<\/em>ex14-positive NSCLC. <em>MET<\/em>ex14 alterations were determined in tissue and liquid biopsy by a next generation sequencing companion diagnostic assay (Archer\u00aeMET, ArcherDX) that gained simultaneous regulatory approval. Data from 99 patients enrolled in the study, including 15 Japanese patients, demonstrated a clinically meaningful benefit with a once-daily dose of 500 mg tepotinib, across different lines of treatment. The overall response rate, assessed by an Independent Review Committee, was 42.4% in patients whose <em>MET <\/em>status was determined by either tissue or liquid biopsy, and the median duration of response was 12.4 months. Tepotinib was well tolerated; the most common treatment-related adverse events (TRAEs) of any grade were peripheral edema (53.8%), nausea (23.8%), and diarrhea (20.8%). Eleven patients (8.5%) discontinued treatment due to TRAEs.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Currently, tepotinib is only approved in Japan. In the United States, tepotinib was granted breakthrough therapy designation by the Food and Drug Administration (FDA) in September 2019 for the treatment of patients with metastatic NSCLC harboring&nbsp;<em>MET<\/em>ex14-skipping alterations whose cancer has progressed following platinum-based chemotherapy. The designation was based on interim data from the VISION trial. Hot on the heels of tepotinib is another selective MET inhibitor, capmatinib (Novartis), which received priority review by the FDA in February 2020 based on the results of the <a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2019.37.15_suppl.9004\" target=\"_blank\" rel=\"noreferrer noopener\">phase II GEOMETRY study<\/a>. These two MET inhibitors, along with other emerging MET-targeted agents evaluated in clinical trials, may improve outcomes for patients with this rare molecular subtype of aggressive lung cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A subset of lung adenocarcinomas (3-4%) harbor oncogeni [&hellip;]<\/p>\n","protected":false},"author":434,"featured_media":683,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[42],"tags":[],"class_list":["post-1319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-42"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations - ACE Oncology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"A subset of lung adenocarcinomas (3-4%) harbor oncogeni [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-24T07:18:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-05T05:18:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/11\/file-1604637025608-12.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1250\" \/>\n\t<meta property=\"og:image:height\" content=\"834\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pascha Paularin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pascha Paularin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/\"},\"author\":{\"name\":\"Pascha Paularin\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33\"},\"headline\":\"Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations\",\"datePublished\":\"2020-04-24T07:18:00+00:00\",\"dateModified\":\"2021-03-05T05:18:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/11\/file-1604637025608-12.jpg\",\"articleSection\":[\"\u65b0\u836f\u83b7\u6279\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/\",\"name\":\"Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/11\/file-1604637025608-12.jpg\",\"datePublished\":\"2020-04-24T07:18:00+00:00\",\"dateModified\":\"2021-03-05T05:18:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/11\/file-1604637025608-12.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/11\/file-1604637025608-12.jpg\",\"width\":1250,\"height\":834,\"caption\":\"ACE-OncoBlog-FDA-approval\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33\",\"name\":\"Pascha Paularin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g\",\"caption\":\"Pascha Paularin\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/ppaschaaceoncology-org\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations - ACE Oncology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/","og_locale":"zh_CN","og_type":"article","og_title":"Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations - ACE Oncology","og_description":"A subset of lung adenocarcinomas (3-4%) harbor oncogeni [&hellip;]","og_url":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/","og_site_name":"ACE Oncology","article_published_time":"2020-04-24T07:18:00+00:00","article_modified_time":"2021-03-05T05:18:27+00:00","og_image":[{"width":1250,"height":834,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/11\/file-1604637025608-12.jpg","type":"image\/jpeg"}],"author":"Pascha Paularin","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"Pascha Paularin","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"2 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/"},"author":{"name":"Pascha Paularin","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33"},"headline":"Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations","datePublished":"2020-04-24T07:18:00+00:00","dateModified":"2021-03-05T05:18:27+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/11\/file-1604637025608-12.jpg","articleSection":["\u65b0\u836f\u83b7\u6279"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/","url":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/","name":"Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/11\/file-1604637025608-12.jpg","datePublished":"2020-04-24T07:18:00+00:00","dateModified":"2021-03-05T05:18:27+00:00","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/11\/file-1604637025608-12.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2020\/11\/file-1604637025608-12.jpg","width":1250,"height":834,"caption":"ACE-OncoBlog-FDA-approval"},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/japan-first-to-approve-met-inhibitor-for-advanced-nsclc-with-met-exon-14-skipping-alterations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"Japan First to Approve MET Inhibitor for Advanced NSCLC with MET exon 14 Skipping Alterations"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/d8f6edf15a20f14b3b57d44c6be51e33","name":"Pascha Paularin","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/521645f985d3ddd8a50c2df03ffbf2a2554ac92274f36d665fac216d09fdf1d8?s=96&d=mm&r=g","caption":"Pascha Paularin"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/ppaschaaceoncology-org\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/1319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/434"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=1319"}],"version-history":[{"count":1,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/1319\/revisions"}],"predecessor-version":[{"id":1320,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/1319\/revisions\/1320"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/683"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=1319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=1319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=1319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}